Abstract
Several years ago triethanomelamine (2,4,6-tri(ethyleneimino)-l,3,5-triazine, or TEM) was introduced into clinical chemotherapy for its tumour-inhibiting property. It was found, in addition, that TEM is a strong mutagenic factor.